CliffBio
small molecule

INVIRASE

SAQUINAVIR MESYLATE

Loss of exclusivity—loss of exclusivity
CompanyHOFFMANN-LA ROCHE INC

Drug detail

Brand nameINVIRASE
Active ingredientSAQUINAVIR MESYLATE
StrengthEQ 500MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2004
Marketing statusDISCN

More from HOFFMANN-LA ROCHE INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

INVIRASE patent cliff — loss of exclusivity — | CliffBio